#USA #Raleigh #financial results #Lumexa Imaging #outpatient imaging

Lumexa Imaging Posts Preliminary Results for 2025

Lumexa Imaging Holdings, Inc. has announced its preliminary unaudited results for the fourth quarter and full year of 2025, showcasing strong growth and a positive outlook for 2026. As one of the largest providers of outpatient imaging services in the United States, Lumexa's performance underscores the increasing demand for such services in the healthcare sector.

Fourth Quarter and Year-End Highlights

Lumexa Imaging expects to close the quarter with consolidated revenues reaching at least $261 million, representing an increase from $248 million in 2024. The anticipated system-wide revenue growth is pegged at over 10%. Although they predict a net loss not greater than $25.4 million compared to a $25.1 million loss the previous year, the company also expects an Adjusted EBITDA of at least $63 million, notably up from $53.7 million.

For the entire year of 2025, expected consolidated revenues are forecasted to be around $1.016 billion, a substantial increase from $948.9 million in the previous year. In contrast, the net loss is anticipated to reduce to $43.8 million from a loss of $94.1 million in 2024. The Adjusted EBITDA for the year is also predicted to rise to at least $229 million, versus $200.8 million the year prior.

Growth Initiatives

Lumexa has been diligently executing its growth strategy, achieving key milestones including:

• - Completing an initial public offering.
• - Effectively reducing leverage and refinancing remaining debts at more favorable rates.
• - Acquiring one site and opening three wholly owned de novo centers.

The company has seen an impressive growth in procedure volumes, with total procedures reaching approximately 2,418,096 in 2025, a 4.6% increase from the previous year. In the fourth quarter alone, advanced procedures grew by 14.2%, highlighting the increasing demand for high-quality outpatient imaging.

Future Outlook for 2026

Looking ahead, Lumexa Imaging expects consolidated revenues for 2026 to range between $1.045 billion and $1.097 billion. The projected Adjusted EBITDA for this coming year is between $234 to $242 million, which accounts for additional public company costs not incurred in 2025. This careful financial planning aims to sustain their growth trajectory while balancing operational costs.

CEO Caitlin Zulla noted, “We closed 2025 with solid growth momentum across our platform. The anticipated Adjusted EBITDA growth of at least 14% compared to last year will be driven by continued demand for advanced imaging and solid performance from our newly opened centers.”

In the coming year, Lumexa intends to expand its services, particularly in PET imaging technologies. They have reported a 17% year-over-year increase in PET volumes as they adapt to evolving healthcare needs, including the use of radiopharmaceuticals for better diagnostic capabilities.

Upcoming Investor Engagement

To discuss the financial results and future outlook, Lumexa Imaging will host an earnings conference call on March 26, 2026, at 8:30 AM ET. Interested participants can register for the call and access the audio webcast at Lumexa's investor relations website.

With a focus on expanding their technology offerings, Lumexa Imaging has launched a pilot program for an AI-powered Breast Arterial Calcification assessment in New Jersey. This innovative technology aims to enhance patient screening options, reflecting Lumexa's commitment to staying at the forefront of imaging advancements.

Conclusion

As Lumexa Imaging continues its disciplined growth strategy, it stands poised to leverage the increasing demand for outpatient imaging. The company’s impressive financial performance in 2025 underlines its potential as a leader in the imaging space, further showing promise in its expansion plans for 2026 and beyond.